• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Cyclo Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results

    11/15/21 4:20:00 PM ET
    $CYTH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CYTH alert in real time by email

    Continued progress in lead development program evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) in ongoing pivotal study (TransportNPC™)

    Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter of 2021, and provided a business update.

    "We have executed on multiple fronts over the course of the third quarter. Our pivotal Phase 3 study evaluating Trappsol® Cyclo™ as a potential treatment for Niemann-Pick Disease, TransportNPC™, is now underway and we are pleased with the progress made thus far. Additionally, we've bolstered the leadership and expertise of our team with the appointments of our Chief Medical Officer and a Senior Advisor for the Alzheimer's disease program, both of whom are world renowned, and we expect will add significant value as we look to advance Trappsol® Cyclo™ through the clinic and potentially to market," commented N. Scott Fine, CEO of Cyclo Therapeutics. "Lastly, we continue to advance towards launching a Phase 2 study for our Alzheimer's disease asset. We continue to execute on all fronts and are well-positioned for what we believe will be an exciting remainder of the year and beyond."

    Recent Highlights

    • Bolstered executive leadership team with appointment of Lise Lund Kjems, MD, PhD as Chief Medical Officer;
    • Named preeminent neuroscientist and world-renowned researcher, Cynthia A. Lemere, PhD, as Senior Advisor for advancement of Alzheimer's Disease program; and
    • Announced new positive safety and efficacy data from ongoing Phase 1 open-label extension study of Trappsol® Cyclo™ for the treatment of NPC.

    Trappsol® Cyclo™ Clinical Program Update

    Trappsol® Cyclo™ is a proprietary formulation of hydroxypropyl beta cyclodextrin, used intravenously (IV) and currently in development for the treatment of NPC, a rare genetic disorder causing cholesterol accumulation in lysosomes of cells, organ dysfunction and premature death.

    Niemann-Pick Disease Type C1 Development Program

    In June 2021, the Company commenced the TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of NPC1, a rare, progressive and fatal genetic disorder. Initial sites are in the U.S.

    The pivotal Phase 3 study is a randomized, double-blind, placebo-controlled, parallel group, multicenter study designed to evaluate the safety, tolerability, and efficacy of 2,000 mg/kg doses of Trappsol® Cyclo™ administered intravenously and standard of care (SOC), compared to placebo administered intravenously and SOC alone, in patients with NPC1. The Phase 3 study intends to enroll at least 93 pediatric (age 3 years and older) and adult patients with NPC1 in at least 23 study centers in 9 countries. Eligible patients will be randomized 2:1 to receive either Trappsol® Cyclo™ or a placebo. Randomization will not be constrained based on patient age, nor will patient enrollment be gated by patient age. The study duration is 96 weeks and includes an interim analysis at 48 weeks.

    The Company received a positive opinion from the Paediatric Committee (PDCO) of the EMA and agreement on its Paediatric Investigation Plan (PIP) for Trappsol® Cyclo™. The PIP opinion from PDCO endorsed the clinical program to evaluate the safety, tolerability and efficacy of Trappsol® Cyclo™ in patients from 3 to less than 18 years of age with NPC in the randomized study, and in addition, to include a single-arm open-label sub-study of patients from birth to less than 3 years of age with NPC Type C1 irrespective of symptoms to evaluate safety and to obtain descriptive data on global disease severity and the response to Trappsol® Cyclo™. The sub-study in patients from birth to less than 3 years of age will only be conducted in the EU and countries following EMA guidelines.

    Additionally, Cyclo Therapeutics recently presented new long-term safety and efficacy data from its ongoing Phase 1 open-label extension study evaluating Trappsol® Cyclo™ for the treatment of NPC. The data seen to-date provide additional support for the capacity of Trappsol® Cyclo™ to stabilize disease progression with home-based intravenous infusions as well as for a favorable safety profile of more than two years in NPC.

    For more information about the Company's TransportNPC™ pivotal Phase 3 study, visit www.ClinicalTrials.gov and reference identifier NCT04860960.

    Cyclo Therapeutics received Orphan Drug Designation for Trappsol® Cyclo™ to treat NPC1 in both the U.S. and EU and Fast Track and Rare Pediatric Disease Designations in the U.S. The Rare Pediatric Disease Designation is one of the chief requirements for sponsors to receive a Priority Review Voucher in the U.S. upon marketing authorization.

    Alzheimer's Disease Asset

    Cyclo Therapeutics is also planning to evaluate Trappsol® Cyclo™ for the treatment of Alzheimer's Disease, targeting the reduction of amyloid beta and tau. As part of a Type B interaction with the FDA, Cyclo Therapeutics received positive feedback supporting the Company's development strategy to submit an IND application for a Phase 2 study of intravenous Trappsol® Cyclo™ in the treatment of early Alzheimer's disease.

    Summary of Financial Results for Third Quarter 2021

    Net loss for the quarter ended September 30, 2021 was approximately $3.8 million. Research and development expenses increased 69% to $1.8 million for the three months ended September 30, 2021, from $1.1 million for the three months ended September 30, 2020. The increase in research and development expense is due to increased activity in the Company's international clinical program and U.S. clinical trials. The Company expects research and development costs to further increase in 2021 as we continue to seek regulatory approval for the use of Trappsol® Cyclo™ in the treatment of NPC and Alzheimer's disease.

    The Company ended the quarter with approximately $8.4 million of cash.

    About Cyclo Therapeutics

    Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company's Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.gov NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer's Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer's Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the Company's website: www.cyclotherapeutics.com.

    Safe Harbor Statement

    This press release contains "forward-looking statements" about the company's current expectations about future results, performance, prospects and opportunities, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company's future performance include the company's ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company's biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

    -- Financial Tables Follow—

     
     

    CYCLO THERAPEUTICS, INC. AND SUBSIDIARIES

    CONSOLIDATED BALANCE SHEETS

     

     

     

     

     

     

     

    September 30,

    2021

     

    December 31,

    2020

     

     

    (Unaudited)

     

     

    ASSETS

    CURRENT ASSETS

     

     

    Cash and cash equivalents

    $

    8,441,297

     

     

    $

    12,846,113

     

    Accounts receivable

     

    354,864

     

     

     

    71,017

     

    Inventory, net

     

    253,797

     

     

     

    237,909

     

    Current portion of mortgage note receivable

     

    45,070

     

     

     

    40,772

     

    Prepaid insurance and services

     

    92,483

     

     

     

    126,474

     

    Prepaid clinical expenses

     

    1,804,664

     

     

     

    727,952

     

    Total current assets

     

    10,992,175

     

     

     

    14,050,237

     

     

     

     

     

    FURNITURE AND EQUIPMENT, NET

     

    63,790

     

     

     

    53,910

     

     

     

     

     

    RIGHT-TO-USE LEASE ASSET, NET

     

    22,044

     

     

     

    34,011

     

     

     

     

     

    MORTGAGE NOTE RECEIVABLE, LESS CURRENT PORTION

     

    18,520

     

     

     

    49,806

     

     

     

     

     

    TOTAL ASSETS

    $

    11,096,529

     

     

    $

    14,187,964

     

     

     

     

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

     

    CURRENT LIABILITIES

     

     

     

    Current portion of lease liability

    $

    18,882

     

     

    $

    17,483

     

    Current portion of note payable

     

    106,836

     

     

     

    114,029

     

    Accounts payable and accrued expenses

     

    3,293,869

     

     

     

    3,541,041

     

    Total current liabilities

     

    3,419,587

     

     

     

    3,672,553

     

     

     

     

     

    LONG-TERM LIABILITIES

     

     

     

    Long-term lease liability, less current portion

     

    4,978

     

     

     

    18,434

     

    Long-term note payable, less current portion

     

    44,910

     

     

     

    44,495

     

    Total long-term liabilities

     

    49,888

     

     

     

    62,929

     

     

     

     

     

    STOCKHOLDERS' EQUITY

     

     

     

    Common stock, par value $.0001 per share, 20,000,000 shares authorized, 6,453,869 and 4,770,761 shares issued and outstanding, at September 30,2021 and December 31, 2020, respectively

     

    646

     

     

     

    477

     

    Preferred stock, par value $.0001 per share, 5,000,000 shares authorized

     

    -

     

     

     

    -

     

    Additional paid-in capital

     

    53,182,513

     

     

     

    44,513,841

     

    Accumulated deficit

     

    (45,556,105

    )

     

     

    (34,061,836

    )

    Total stockholders' equity

     

    7,627,054

     

     

     

    10,452,482

     

     

     

     

     

    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

    $

    11,096,529

     

     

    $

    14,187,964

     

    CYCLO THERAPEUTICS, INC. AND SUBSIDIARIES

    CONSOLIDATED STATEMENTS OF OPERATIONS

    (Unaudited)

     

     

     

     

     

     

     

    Three Months Ended

     

    Nine Months Ended

     

     

    September 30,

     

    September 30,

     

     

    2021

     

    2020

     

    2021

     

    2020

     

     

     

     

     

    REVENUES

     

     

     

     

    Product sales

    $

    403,918

     

    $

    222,462

     

    $

    1,000,641

     

    $

    757,790

     

     

     

     

     

     

    EXPENSES

     

     

     

     

    Personnel

     

    1,668,010

     

     

    424,823

     

     

    2,769,526

     

     

    1,328,156

     

    Cost of products sold (exclusive of direct and indirect overhead and handling costs)

     

    22,671

     

     

    11,578

     

     

    87,425

     

     

    50,958

     

    Research and development

     

    1,837,720

     

     

    1,086,753

     

     

    7,739,379

     

     

    4,859,794

     

    Repairs and maintenance

     

    2,425

     

     

    1,408

     

     

    5,738

     

     

    4,521

     

    Professional fees

     

    450,490

     

     

    72,319

     

     

    1,046,979

     

     

    435,282

     

    Office and other

     

    244,343

     

     

    48,202

     

     

    799,856

     

     

    306,387

     

    Board of Director fees and costs

     

    30,708

     

     

    9,718

     

     

    30,708

     

     

    38,434

     

    Depreciation

     

    4,207

     

     

    3,117

     

     

    12,620

     

     

    9,353

     

    Freight and shipping

     

    2,360

     

     

    543

     

     

    5,154

     

     

    3,575

     

    Bad debt expense

     

    -

     

     

    -

     

     

    -

     

     

    1,272

     

    Total operating expenses

     

    4,262,934

     

     

    1,658,461

     

     

    12,497,385

     

     

    7,037,732

     

     

     

     

     

     

    LOSS FROM OPERATIONS

     

    (3,859,016

    )

     

    (1,435,999

    )

     

    (11,496,744

    )

     

    (6,279,942

    )

     

     

     

     

     

    OTHER INCOME (EXPENSE)

     

     

     

     

    Investment and other income (expense)

     

    (1,240

    )

     

    390

     

     

    2,475

     

     

    17,949

     

     

     

     

     

     

    LOSS BEFORE INCOME TAXES

     

    (3,860,256

    )

     

    (1,435,609

    )

     

    (11,494,269

    )

     

    (6,261,993

    )

     

     

     

     

     

    PROVISION FOR INCOME TAXES

     

    -

     

     

    -

     

     

    -

     

     

    -

     

     

     

     

     

     

    NET LOSS

    $

    (3,860,256

    )

    $

    (1,435,609

    )

    $

    (11,494,269

    )

    $

    (6,261,993

    )

     

     

     

     

     

    BASIC AND DILUTED NET LOSS PER COMMON SHARE

    $

    (0.60

    )

    $

    (0.94

    )

    $

    (1.90

    )

    $

    (4.34

    )

     

     

     

     

     

    WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING

     

    6,447,803

     

     

    1,519,457

     

     

    6,040,524

     

     

    1,443,109

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20211115006216/en/

    Get the next $CYTH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CYTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CYTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

      NEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced the closing of their business combination following approval by shareholders of both companies. Rafael Holdings issued shares of its Class B common stock to Cyclo Therapeutics' shareholders representing approximately 22% of the combined company, based on the exchange ratio in the merger agreement between the parties determined to be 0.3525. Rafael also issued warrants to purchase shares of Rafael Class B common stock to certain holders of Cyclo warrants. Rafael Holdings has identified Trappsol® Cyclo™ as its lead clinical asset

      3/26/25 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

      The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals Post-merger the Company intends to focus its efforts on Cyclo's lead clinical program Trappsol® Cyclo™ NEWARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), today reported its financial results for the second quarter and first six months of fiscal year 2025 ended January 31, 2025. "We look forward to the upcoming shareholder vote on our pending merger with Cyclo Therapeutics (NASDAQ:CYTH) later this month and anticipate closing promptly post shareholder approvals. Upon closing, the Company's strategic focus will be on its lead clinical asset, T

      3/13/25 5:50:30 PM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)

      First data in NPC1 on treatment in this age group over a period of 48 weeks At 24 weeks of the sub-study, 7 of 8 patients (87%) and at 48 weeks of the sub-study, 6 of 7 patients (86%) show stabilization or improvement in Clinical Global Impression – Change (CGI-C) Scale Data presented at the 21st Annual WORLDSymposium™ 2025 Company on track for topline data from the 48-week interim analysis of 104 enrolled patients in TransportNPC™ in H1 2025 Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with rare and

      2/7/25 8:05:00 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CYTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group reiterated coverage on Cyclo Therapeutics with a new price target

      Maxim Group reiterated coverage of Cyclo Therapeutics with a rating of Buy and set a new price target of $25.00 from $12.00 previously

      2/10/21 8:07:06 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CYTH
    SEC Filings

    See more
    • SEC Form 15-12G filed by Cyclo Therapeutics Inc.

      15-12G - Cyclo Therapeutics, Inc. (0000922247) (Filer)

      4/7/25 4:05:19 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cyclo Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)

      3/26/25 7:05:41 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cyclo Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)

      3/24/25 4:30:22 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CYTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Conkling William was granted 27,654 shares, increasing direct ownership by 55% to 77,884 units (SEC Form 4)

      4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)

      3/3/25 11:45:25 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Wong Vivien was granted 25,140 shares, increasing direct ownership by 63% to 64,853 units (SEC Form 4)

      4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)

      3/3/25 11:45:00 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Cross Shawn was granted 28,597 shares, increasing direct ownership by 27% to 136,346 units (SEC Form 4)

      4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)

      3/3/25 11:44:36 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CYTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Cyclo Therapeutics Inc. (Amendment)

      SC 13G/A - Cyclo Therapeutics, Inc. (0000922247) (Subject)

      2/14/24 2:44:54 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Cyclo Therapeutics Inc. (Amendment)

      SC 13G/A - Cyclo Therapeutics, Inc. (0000922247) (Subject)

      2/14/23 12:30:13 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Cyclo Therapeutics Inc.

      SC 13G - Cyclo Therapeutics, Inc. (0000922247) (Subject)

      2/10/23 4:28:56 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CYTH
    Leadership Updates

    Live Leadership Updates

    See more
    • Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common

      8/22/24 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common stock to Cyclo Therapeutics' shareholders, based on an exchange ratio

      8/22/24 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Cyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease

      – Dr. Hastings is a world-renowned Key Opinion Leader for Niemann-Pick Disease Type C1 and the first physician in the U.S. to use cyclodextrins for treatment in NPC, compassionate use – Site activation ongoing and currently enrolling patients in pivotal Phase 3 study, TransportNPC™ – Data seen to-date provide support for the capacity of Trappsol® Cyclo™ to stabilize disease progression with home-based intravenous infusions in NPC and demonstrate acceptable safety profile of Trappsol® Cyclo™ administered intravenously for more than 2 years Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-cha

      12/9/21 8:05:00 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care